Oncologie Received $80 Million in Series B Financing, Focusing On Tumor Immunotherapy

According to PE Daily, On June 11, 2019, Oncologie just received 80 million dollars in Series B financing, this round of financing was led by Pivotal Bio Venture Partners and Nan Fung Group, and followed by Panacea Venture, Yunhong Capital, Korea Investment Partners and few other investment groups.

Oncologie is a new company specializing in tumor immunotherapy. It currently has three clinical products, mainly dealing with multiple solid tumor indications such as liver cancer, stomach cancer, lung cancer and melanoma. This round of financing will be mainly used to accelerate the clinical research of the company's new products, as well as the corresponding development of new biomarkers.     

"Oncologie is an innovative company that develops globally-owned Best-in-Class anti-tumor drugs and focuses on sales in China. We have an experienced global team and a global drug development platform. Combination therapy is a key direction to improve the effectiveness of tumor immunotherapy and has great market potential. We hope to develop new anticancer drugs for cancer patients around the world," The Co-Founder and CEO of Oncologie Laura Benjamin said.

Pivotal Bio Venture Partners is a $300 million life sciences venture capital fund established in 2017. They invest in privately held North American and European companies focused on innovative therapeutic products and platforms to address major unmet medical needs.

Nan Fung Group is a property developer with global interests in property markets, financial investments, shipping, and hotel investment.

Panacea Venture is a venture capital firm specializing in early and growth stage investments. The firm seeks to invest in health care and life sciences companies with a link to China.

KIP is a leading venture capital & private equity firm that has over 30 years of experience in providing venture capital to bold and innovative entrepreneurs who want to change the world.